erlotinib hydrochloride has been researched along with honokiol in 2 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (honokiol) | Trials (honokiol) | Recent Studies (post-2010) (honokiol) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 816 | 1 | 586 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | honokiol (IC50) |
---|---|---|---|
Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 1.39 | |
TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | 48.8 | |
high affinity choline transporter 1 isoform a | Homo sapiens (human) | 12.0226 | |
Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.2 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arbiser, JL; Bhola, NE; Cai, Q; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Neill, DB; Thomas, SM | 1 |
Anandharaj, A; Hong, KH; Kassie, F; Kim, JH; Kirtane, AR; Panyam, J; Song, JM; Upadhyaya, P | 1 |
2 other study(ies) available for erlotinib hydrochloride and honokiol
Article | Year |
---|---|
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lignans; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Biphenyl Compounds; Bronchi; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Survival; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Lignans; Lung Neoplasms; Magnolia; Mice; Molecular Docking Simulation; Nitrosamines; Plant Extracts; RNA, Small Interfering | 2016 |